Nima Farzan, Kinnate CEO

Kin­nate gets $98M Se­ries C to push pre­ci­sion on­col­o­gy drugs to the clin­ic

Less than a year af­ter bank­ing $74.5 mil­lion in a Se­ries B, San Diego-based Kin­nate Bio­phar­ma is fol­low­ing up with a Se­ries C to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.